Quelle: Medlinie Abstract

HIV-Infektionen (AIDS): Seit Einführung der modernen antiretroviral wirkenden Medikamente hat sich das im Vergleich zur Gesamtbevölkerung in der Vergangenheit dramatisch erhöhte zusätzliche Sterberisiko bei HIV-Patienten  deutlich vermindert.
In den Jahren 2004-2006 konnte in den ersten fünf Jahren nach Serokonversion kein erhöhtes statistisches Sterberisiko festgestellt werden.  Über zehn Jahre wurde in der Altersgruppe von 15-24 Jahren lediglich ein erhöhtes Sterberisiko von 4,8% gefunden werden.

Die vollständige englischsprachige Kurzversion dieser Studie (sog. MEDLINE Abstract) finden Sie hier

 Changes in the risk of death after HIV seroconversion compared with mortality in the general population.

JAMA. 2008 Jul 2;300(1):51-9. PMID: 18594040
Bhaskaran K, et al.

Abstract

CONTEXT: Mortality among human immunodeficiency virus (HIV)-infected individuals has decreased dramatically in countries with good access to treatment and may now be close to mortality in the general uninfected population.

OBJECTIVE: To evaluate changes in the mortality gap between HIV-infected individuals and the general uninfected population.

 DESIGN, SETTING, AND POPULATION: Mortality following HIV seroconversion in a large multinational collaboration of HIV seroconverter cohorts (CASCADE) was compared with expected mortality, calculated by applying general population death rates matched on demographic factors. A Poisson-based model adjusted for duration of infection was constructed to assess changes over calendar time in the excess mortality among HIV-infected individuals. Data pooled in September 2007 were analyzed in March 2008, covering years at risk 1981-2006.

MAIN OUTCOME MEASURE: Excess mortality among HIV-infected individuals compared with that of the general uninfected population.

RESULTS: Of 16,534 individuals with median duration of follow-up of 6.3 years (range, 1 day to 23.8 years), 2571 died, compared with 235 deaths expected in an equivalent general population cohort. The excess mortality rate (per 1000 person-years) decreased from 40.8 (95% confidence interval [CI], 38.5-43.0; 1275.9 excess deaths in 31,302 person-years) before the introduction of highly active antiretroviral therapy (pre-1996) to 6.1 (95% CI, 4.8-7.4; 89.6 excess deaths in 14,703 person-years) in 2004-2006 (adjusted excess hazard ratio, 0.05 [95% CI, 0.03-0.09] for 2004-2006 vs pre-1996).

By 2004-2006, no excess mortality was observed in the first 5 years following HIV seroconversion among those infected sexually, though a cumulative excess probability of death remained over the longer term (4.8% [95% CI, 2.5%-8.6%] in the first 10 years among those aged 15-24 years).

CONCLUSIONS: Mortality rates for HIV-infected persons have become much closer to general mortality rates since the introduction of highly active antiretroviral therapy. In industrialized countries, persons infected sexually with HIV now appear to experience mortality rates similar to those of the general population in the first 5 years following infection, though a mortality excess remains as duration of HIV infection lengthens.

 

	Populäre Allergie-Websites  ..       im Info-Netzwerk Medizin 2000
		Allergietherapie allgemein
		Allergietherapie Newsletter
		Gräser -Impf-Tablette
		Hausstaub(milben)-Allergie
		Insektengift-Allergie (Bienen- und Wespengift-Allergie )
		Lebensmittel-/Nahrungsmittel-Allergie
		Latex-Allergie
		Pollen-Allergie
		Pollen-Asthma-Therapie
		spezifische subkutane Immuntherapie (SCIT)
		sublinguale spezifische Immuntherapie (SLIT)
		Tierhaarallergie ( Hunde- und Katzenhaar-Allergie)
		unspezifische Immuntherapie / -Desensibilisierung
		Wikipedia zu Themen aus der Allergologie